Start your own journey to clinic

Please provide us with a few details so that we can match you with the right expert in your field.

*Required

Thank you, your request has been received.

We're busy connecting you with an expert, who will be in touch as soon as possible.

Oops! Something went wrong while submitting the form. Please try again or email us at webenquiries@conceptlifesciences.com

Disease Modelling

Biomedical research is experiencing a significant shift toward human-centric disease models, driven by the notable failure rates in current drug development processes. A drug candidate's entry into clinical trials heavily relies on efficacy and safety data derived from animal models. However, animal models frequently fail to effectively screen out harmful or ineffective drugs and can also exclude potentially effective drug candidates from entering clinical trials. Therefore, human-based models serve as indispensable tools throughout the drug development journey

Connected servicesMore informationSpeak to an expert

A more in-depth view

Selecting the most appropriate model system is crucial to accurately recapitulate specific aspects of pathology. Different model systems have their advantages and limitations, and the choice depends on various factors, such as the nature of the pathology and the research goals. In response to the notable attrition rates in current drug development, there has been a shift in biomedical research towards human-based disease models, as well as complex model systems such as 3D and organotypic culture systems. While human-based preclinical models, and particularly iPSC-derived models, hold great promise to boost the success rate of drug development, and might even render animal models superfluous in the future, a deeper understanding of their physiology, epigenetic and gene expression profile will need to be achieved before they can be exclusively relied upon.

Concept Life Sciences offers a wide array of human and murine disease models covering various physiological and pathological conditions including those relating to neurodegeneration, immuno-oncology, inflammation and autoimmunity, and Fibrosis. Our assays suit diverse projects and can be tailored by our skilled and knowledgeable scientists based on your individual requirements.  

Our platform offers: 

  • Assay Complexity: Models range from simple monoculture assays to more intricate versions involving two or more cell types.  
  • Cell Diversity: Utilizes cell lines, primary cells, iPSC-derived cells, or combinations thereof within the assays.  
  • Culture System Variability: Assays are conducted in both 2D and 3D culture systems, expanding the scope and depth of modelling capabilities.

Connected resources